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Abstract
Background: Angiogenesis, the formation of new blood vessels, has become an important target in cancer
therapy. Angiogenesis plays an important role in tumor growth and metastasis. Koetjapic acid (KA) is a seco-A-ring
oleanene triterpene isolated from S. koetjape. The solvent extract of this plant species was shown previously to
have strong antiangiogenic activity; however the active ingredient(s) that conferred the biological activity and the
mode of action was not established. Given the high concentration of KA in S. koetjape, an attempt has been made
in this study to investigate the antiangiogenic properties of KA.
Results: Treatment with 10-50 μg/ml KA resulted in dose dependent inhibition of new blood vessels growth in ex
vivo rat aortic ring assay. KA was found to be non-cytotoxic against HUVECs with IC50 40.97 ± 0.37 μg/ml. KA
inhibited major angiogenesis process steps, endothelial cell migration and differentiation as well as VEGF
expression.
Conclusions: The non-cytotoxic compound, KA, may be a potent antiangiogenic agent; its activity may be
attributed to inhibition of endothelial cells migration and differentiation as well VEGF suppression.
Background
Angiogenesis research is the cutting edge technology
that is currently being heavily exploited in the cancer
field [1]. Angiogenesis research will probably change the
face of medicine in the next decades; more than 500
million people worldwide are expected to benefit from
pro- or antiangiogenesis treatments [2]. Angiogenesis is
a process of new blood vessel development orchestrated
by a range of angiogenic factors and inhibitors. This
process is tightly regulated and self limiting in some
cases such as wound healing, normal growth process
and reproductive function [3]. In contrast, when this
process is deregulated, diseases such as cancer, rheuma-
toid arthritis, obesity and diabetic blindness can be
formed [2,4]. Angiogenesis plays an important role in
cancer growth without which, tumors will be unable to
expand beyond 1 to 2 mm3 [5]. Cancer cells within the
tumor will then use the newly formed blood vessels as a
port to metastasize to other localities [6].
Since the interdependency and a close relationship
between angiogenesis, cancer growth and metastasis has
been well-established, much effort have been invested
into development or discovery of antiangiogenic com-
pounds to target cancer and variety of other angiogenic
related ailments.
Angiogenesis inhibitors exhibited their activity via
direct or indirect machineries. The direct angiogenesis
inhibitors interfere with the endothelial cell functions
such as proliferation, migration and differentiation. On
the contrary, indirect angiogenesis inhibitors prohibit
the pro-angiogenic communication between the tumor-
cell and endothelial-cell compartments by decreasing of
angiogenic signals expression, or interference with bind-
ing of these signals with the receptors on the endothelial
cells.
S. koetjape is a terpenoids-rich traditional medicinal
plant belonging to the family Meliaceae, native to
Malaysia, Cambodia and Southern Laos [7]. Our
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previous studies reported strong anti-angiogenic effect
of n-hexane extract of S. koetjape on human colon can-
cer cell lines, however, the underlying mechanism was
not known [8]. Koetjapic acid (KA) is a seco-A-ring
oleanene triterpene isolated from S. koetjape (Figure 1).
KA was found to have poor cytotoxicity on a number of
human cancer cell lines and murine lymphocytic leuke-
mia [7]. KA was also shown to have ichthyotoxic and
chemopreventive effects [9]. In this study, an attempt
has been made to investigate the antiangiogenic activity
of KA in vitro and in vivo.
Results
KA inhibits the sprouting of microvessels in rat aortic
rings
The anti-angiogenic potential of KA was investigated
firstly in the rat aortic model. Figure (2A) shows the
microvessels outgrowth from the untreated aortic rings.
On the contrary, aortic rings treated with KA exhibited
reduced outgrowth with IC50 16.8 ± 1.7 μg/ml (Figure
2B and 2C). The anti-angiogenic effect on explants of
rat aorta showed a significant dose dependent relation-
ship (P < 0.05). At 20 μg/ml, KA inhibited vascularisa-
tion by 50% and doubling the dose to 40 μg/ml led to a
complete inhibition of angiogenesis by 100%. Suramin,
which was used as a positive control showed almost
100% inhibition of microvessels outgrowth at 100 μg/ml
(Figure 2D).
Effect of KA on HUVECs Proliferation
KA was found non cytotoxic agent against HUVECs as
the IC50 value was found to be 40.97 ± 0.37 μg/ml. At
concentration of 20 μg/ml, KA causes no significant inhi-
bition on HUVECs proliferation (P > 0.05). Figure (3)
Figure 1 Chemical structure of KA. The structure of KA has been
resolved by X-ray crystallography as described previously [18].
Figure 2 Effects of KA on angiogenesis in rat aortic ring assay.
Effect of KA on microvessels formation in rat aortic rings. Explants
treated with (A) 1% ethanol (B) 10 μg/ml (C) 40 μg/ml and (D) 100
μg/ml suramin as a positive control (4X). (E) The Dose response
relationship of KA on rat aorta assay. Data was represented as mean
± SD (n = 3). *P <0.05 and ***P <0.001.
Figure 3 Effects of KA on HUVECs proliferation. Effects of KA on
HUVECs viability. KA inhibits proliferation of HUVECs in dose
dependent manner. Values are means of three experiments (n = 3).
Data presented in mean ± SD.
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demonstrates the dose dependent activity of KA on
HUVECs proliferation.
KA Inhibits HUVECs Migration
Effect of KA on endothelial cell migration was studied
using endothelial cell migration wound healing assay.
Significant reduction in HUVECs motility was achieved
at 10 μg/ml with 6.9 ± 1.19% and 10.6 ± 2.31% inhibi-
tion at 12 and 18 h treatment, respectively (P < 0.05)
(Figure 4). At 20 μg/ml, KA inhibited HUVECs migra-
tion by 27.3 ± 3.1% and 23.6 ± 1.28% after 12 h and 18
h incubation period, respectively (P < 0.001).
KA Inhibits Differentiation of HUVECs on Matrigel Matrix
In normal setting, endothelial cells will form tube-like
structure networks in a matrigel matrix within 6 h.
Treatment of HUVECs with KA inhibited the growth
factors induced differentiation in a dose-dependent
manner. At lower concentrations, KA reduced the area
occupied by the network structures and incomplete and
broken tubules were formed (Figure 5). At 40 μg/ml,
KA completely abrogated endothelial tube formation.
The IC50 value was 14.07 ± 2.74 μg/ml comparable with
that of the suramin positive control.
KA Inhibits VEGF Expression
KA caused significant inhibition of VEGF level in
HUVECs. KA at 20 μg/ml suppressed VEGF expression
by 30.68%. The VEGF concentration in cell lysates of
treated HUVECs at 20 μg/ml was 262 ± 22.37 pg/ml
and was significantly lower than untreated cells which
was 378 ± 13.09 pg/ml (P < 0.001).
In vivo CAM Assay
Vascularisation in chick embryo was significantly inhib-
ited by KA at 100 and 50 μg/disc. The displayed images
in Figure 6 show normal vasculature pattern in the
untreated CAMs with primary, secondary and tertiary
vessels and dendritic branching pattern. On the other
hand, the 100 and 50 μg KA-treated CAM showed dis-
torted architecture in the vasculature. The number of
the blood vessels was decreased significantly in treated
CAMs. KA inhibited the formation of new blood vessels
significantly by 41.8 ± 7.2% and 64.9 ± 8.7% at 50 and
100 μg respectively, when compared to the control.
Discussion
Recently more efforts have been concentrated on synth-
esis or discovery of non-cytotoxic compounds that have
antiangiogenic and anti-neoplastic activity. This treat-
ment approach decreases the side effects that accompany
the classical chemotherapeutics drugs. Angiogenesis
involves a series of processes including activation of the
endothelial cells, degradation of the basement membrane,
endothelial cell migration, proliferation of the endothelial
cells, vessels elongation, vessels branching, vasodilatation,
formation of basement membrane, acquisition of peri-
cyte, and re-modelling [10]. Cancer colonies remain
undetected and dormant for several years, and under cer-
tain circumstances the tumor cells switch into angiogenic
Figure 4 Effects of KA on HUVECs Migration. A scratch is created and then the cells were treated with 1% ethanol or 10 and 20 μg/ml of KA.
At 0, 12 and 18 h, pictures of the wounds were captured at 4X magnification.
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Figure 5 Effects of KA on HUVECs Differentiation. Effect of KA on matrigel tube formation of endothelial cells. Cells treated with (A) 1% ethanol
(B) 10 μg/ml (C) 20 μg/ml and (D) 30 μg/ml (E) 40 μg/ml and (F) 100 μg/ml suramin as a positive control (4X). (G) The Dose response relationship
of KA on rat aorta assay. The inhibitory effect was found to be in dose response manner. Data was represented as mean ± SD (n = 3). ***P <0.001.
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phenotype, induce formation of new blood vessels, then
start to grow and metastasize to other localities [11]. The
angiogenic switch takes place when the positive angio-
genic factors such as VEGF outweigh the negative factors
such as endostatin [12]. Therefore, the angiogenic switch
may result from over production of VEGF. Many studies
have been focused on screening novel non-cytotoxic
compounds or extracts from natural products but have
antiangiogenic properties [13,14]. KA has found to have
antibacterial, anti-inflammatory, anti-tumor promoting
activity and DNA polymerase inhibition properties
[9,15-17]. Till now, there are no reports about antiangio-
genic activity of KA. Previously we have shown that the
hexane extract of Sandoricum koetjape have a strong
antiangiogenic activity ex vivo [8]. Fractionation and crys-
tallization of the extract has led to the isolation of KA
[18].
In this study, a battery of well established angiogenesis
assays was employed to evaluate the antiangiogenic
activity of KA. The results showed that KA perturbed
the new blood vessels formation in rat aortic ring
explants with IC50 of 16.8 ± 1.7 μg/ml (Figure 2). The
effect of KA on HUVECs proliferation has been con-
ducted to measure if the antiangiogenic activity
observed was due to cytotoxic activity towards the
endothelial cells or anti-proliferative activity. The MTT
results showed that KA is not cytotoxic towards the
endothelial cells and the IC50 value was at 40.97 ± 0.37
μg/ml. Furthermore, it has no significant effect on cells
proliferation at 20 μg/ml (P > 0.05) (Figure 3). The cyto-
toxicity results are compatible with the previous work
on anticancer activity of this compound [7]. On the
other hand, KA inhibited 100% of the angiogenesis pro-
cess in the ex vivo rat aortic ring model at a dose of 40
μg/ml and around 50% at a dose of 20 μg/ml of KA.
Taken together, the results of rat aortic ring assay and
the MTT assay on HUVECs confirmed that the antian-
giogenic effect demonstrated by KA is not due to the
cytotoxic nature of the compound, but may be more
related to inhibition of one or more of other angiogen-
esis cascade.
In order to investigate the angiogenesis inhibitory
mechanisms of KA, we have studied its effects on three
major steps in angiogenesis namely, endothelial cells
migration, endothelial cells differentiation and VEGF
expression. KA inhibits all of these processes signifi-
cantly at a dose 20 μg/ml at a dose that is below the
cytotoxic concentration. At 20 μg/ml, the compound
inhibits 31% of VEGF expression in HUVECs. VEGF is
regarded as the major growth factor that triggers the
angiogenesis event. It is responsible for triggering var-
ious steps in the angiogenesis cascade such as prolifera-
tion, migration and cell survival [19]. VEGF has been
found significantly up-regulated at the levels of RNA
and protein in most types of cancer. The high concen-
tration of VEGF in cancer patients is associated with
poor prognosis as well as with low survival [20]. During
the angiogenesis cascade, the extracellular matrix and
vascular basement membrane are degraded, permitting
the endothelial cells to migrate into the perivascular
Figure 6 Effects of KA on neovascularization in CAM assay. Effect
of KA on neovascularization in chorioallantoic membrane of chick
embryo. The embryos were treated for 24 h with (A) 1% ethanol as a
negative control, (B) 50 μg/ml and (C) 100 μg/ml. The pictures were
captured under dissecting microscope. Arrows indicate the place of
agarose discs application. KA inhibited the neovascularisation in a
dose-dependent manner by 41.8 ± 7.2% and 64.9 ± 8.7% at 50 and
100 μg respectively. Data presented in mean ± SD.
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space in the direction of angiogenic stimuli. At a con-
centration of 20 μg/ml, KA inhibited HUVECs migra-
tion by 27.3 ± 3.1% and 23.6 ± 1.28% after 12 h and 18
h incubation period, respectively (P <0.001) (Figure 4).
Nitric oxide (NO) has been identified as an endothe-
lium-derived relaxing factor (EDRF) [21], which induces
endothelial cell proliferation and migration [22,23].
Thus, no wonder that EDRF/NO has been revealed to
play a crucial role in angiogenesis process regulation
[24]. VEGF has been shown to stimulate endothelial NO
production [25-27], additionally, many reports have
shown that eNOS lies downstream of VEGF and both
are under the target of HIF-1 transcriptional factor [28].
The ability of KA to inhibit the endothelial cells migra-
tion may be implicated to inhibition of VEGF produc-
tion and consequently inhibition of nitric oxide
signaling.
After cells migrate into the perivascular space,
HUEVCs differentiate so their shapes change in a way
that facilitates the adherence amongst the cells to form
a lumen (tube-like structure) [29]. KA inhibited the for-
mation of such tube like structures in a dose dependent
relationship (Figure 5). At the concentration equal to
IC50 against HUVECs proliferation (40 μg/ml), KA
inhibited tube formation by 91%, and at the non-toxic
dose (20 μg/ml), tube formation inhibition was around
60%. Endothelial cells differentiation requires activation
of VEGFR-1 (FLt-1) [30]. The significant inhibition of
VEGF expression by KA may play role in VEGFR-1 acti-
vation and consequently inhibition of HUVECs
differentiation.
The final step in this study was to test if the KA can
exhibit its antiangiogenic properties in vivo as it did in
in vitro and ex vivo assays. The vascularisation in chick
embryo was significantly inhibited by the compound at
50 μg and 100 μg (Figure 6). The results of this study
show that KA inhibited many crucial steps of the angio-
genesis process hence it may be useful in treating angio-
genesis related ailments such as cancer.
Conclusions
In conclusion, this study demonstrates that KA can inhi-
bit neovascularisation by affecting VEGF expression,
endothelial cell migration and endothelial tube
formation.
Material and methods
Cell lines and Culture Conditions
Human umbilical vein endothelial cells (HUVECs); Cat-
alogue number (8000) was purchased from ScienCell,
USA. HUVECs were maintained in ECM medium sup-
plemented with 5% HIFBS, 1% PS and 1% ECGS. Cells
were cultured in a 5% CO2 in a humidified atmosphere
at 37°C.
Chemicals and Reagents
Endothelial Cell Medium (ECM) supplied with endothe-
lial cell growth supplements (ECGS) was purchased
from ScienCell, USA. trypsin and heat inactivated foetal
bovine serum (HIFBS) were obtained from GIBCO, UK.
Human VEGF assay kit was obtained from Raybio, USA.
Phosphate buffered saline (PBS), penicillin/streptomycin
(PS) solution, MTT reagent, suramin, amphotericin B,
aprotinin, 6-aminocaproic acid, L-glutamine, thrombin,
gentamicin were purchased from Sigma-Aldrich, USA.
Fibrinogen was supplied by Calbiochem, USA. Matrigel
matrix (10 mg/ml) was purchased from BD Bioscience,
USA. Other chemicals and solvents were of analytical
grade.
Experimental Animal
The 12-14 weeks old Sprague Dawley male rats were
obtained from the animal house facility of USM. All
procedures were carried out in accordance with the
guidelines of USM Animal Ethical Committee. The ani-
mals were kept for one week in transient animal house
(School of Pharmaceutical Sciences, USM) prior to the
experiment. The animals were kept in well ventilated
cages at 12 h light cycle with food and water ad libitum.
The animals were humanely sacrificed under CO2.
Koetjapic Acid
KA was isolated the from S. koetjape stem bark as
described previously [18]. Briefly, 10 g of n-hexane
extract was crystallized at -20°C in 50 ml methanol:
acetone at 1:1 v/v. The collected crystals (500 mg) were
re-crystallized in chloroform by solvent evaporation to
give 400 mg colourless prism-shaped crystals (0.2%).
The three dimensional structure of the compound was
elucidated by X-ray crystallography as described pre-
viously [18].
KA was dissolved in ethanol to obtain 10 mg/ml stock
solution and stored at 4°C. For drug treatment, KA was
diluted in indicated culture medium at the indicated
concentrations in each experiment.
Cell Proliferation Assay
Cytotoxicity of the KA was evaluated by MTT assay.
Cells were treated for 48 h with KA or 1% ethanol as a
negative control. Viability of cells were determined by
MTT test as described previously [31]. Assay plates
were read using a microtiter plate reader (Hitachi U-
2000, Japan) at A570. The results are presented as per-
cent viability to the negative control (n = 3).
Ex vivo Rat Aortic Ring Assay
The rat aortic ring assay was carried out according to
techniques established by Brown et al (1996) with slight
modification [32]. In brief, aortic rings (1 mm thickness)
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taken from thoracic aortas of 12-14 weeks old male
Sprague Dawley rats were seeded individually in 48-
wells plate in 300 μl serum free M199 media containing
3 mg ml-1 fibrinogen and 5 mg ml-1 aprotinin. 50 NIH
U ml-1 thrombin in 0.15 M NaCl were added in each
well. After 90 min incubation at 37°C, various concen-
trations of KA dissolved in 0.3 ml M 199 medium sup-
plemented with 20% HIFBS, 0.1% έ-aminocaproic acid,
1% L-Glutamine, 2.5 μg/ml amphotericin B, and 60 μg/
ml gentamicin, were added to each well. Suramin and
1% ethanol were used as positive and negative controls,
respectively. On day four, the medium was replaced
with a fresh one containing the compound. On day five,
aortic rings were photographed at 4x magnification
using an inverted light microscope (Olympus). The
angiogenic response was determined by measuring the
distance of blood vessels outgrowth from the primary
tissue ex-plants using the same instrument with the aid
of Leica Quin software package [33]. The results are
presented as mean percent inhibition to the negative
control ± SD, (n = 3).
Migration Assay
The assay was carried out as prescribed previously [34].
Briefly, HUVECs were plated in 6 well plates till the for-
mation of a confluent monolayer after which a wound
was created with 200 μl micropipette tips. The detached
cells were removed by washing twice with PBS and the
plates were treated with KA. The wounds were photo-
graphed after 12 and 18 h, and the width of the cell-free
wounds was measured using an inverted light micro-
scope supplied with Leica Quin computerized imaging
system. 10 fields per well were photographed and mini-
mum of 30 readings per field were taken. The results
are presented as mean percentage of migration inhibi-
tion compared to control ± SD, (n = 3).
Tube Formation Assay
The ability of HUVECs to form tube-like structures was
investigated on a matrigel matrix. In Brief, the matrigel
matrix was allowed to polymerize for 45 min at 37°C
and 5% CO2. HUVECs were trypsinized and seeded (3 ×
104 cells per well) in 100 μl of ECM containing various
concentrations of KA in triplicates. After 6 h tubular
structures were imaged under an inverted light micro-
scope at 4X magnification. The quantitative assessment
of tube formation inhibition was achieved by measuring
the area occupied by tubular structures using the Scion
Image analysis program [35]. The results are presented
as a mean percentage of inhibition ± SD, (n = 3).
Determination of VEGF Concentration in HUVECs Lysates
VEGF concentration was determined using a human
VEGF-165 ELISA kit (Raybio, USA) as per the
manufacturer’s instructions. According to the manufac-
turer, the minimum detectable concentration of VEGF
is less than 20 pg/ml. Briefly, 60-70% confluent cultures
of HUEVCs were treated with KA at 20 μg/ml for 6 h,
and cell lysates were prepared using cell lysis buffer pro-
vided along with the kit. At the time of the experiment
a calibration curve of VEGF standard was prepared. The
concentration of VEGF in cell lysates was calculated
using the log-log regression equation of the best fit line
of the standard calibration curve; (y = 0.0099 × 0.6137, R2
= 0.996). The experiment was repeated twice in
triplicates.
In vivo CAM Assay
Antiangiogenic effect of KA was investigated in vivo in
CAM assay as mentioned previously [36]. Five Day-old
fertilized eggs were obtained from local hatchery. 5 ml of
albumin was aspirated and the eggs were incubated hori-
zontally to allow the CAM to detach from the shell. KA
was prepared in agarose 1.2% discs at 100 or 50 μg/disc.
Discs containing the vehicle only (ethanol) were used as
negative control. Then a small window opening was
made in the shell, and the discs were directly applied
onto the CAM. The square opening was covered with
sterilised surgical tape and the embryos were incubated
for 24 h. The CAMs were photographed under a dissect-
ing microscope and blood vessels in each CAM were
counted. The results are presented as a mean percentage
of inhibition comparing to control ± SD, (n = 3).
Statistical Analysis
Results were presented as means ± SD and differences
between groups were compared by the one way
ANOVA and considered significant at P < 0.05, 0.01 or
0.001. The statistical analysis was carried out by using
SSPS edition 16.0.
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